Clinical trial
A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
NCT07062198 is registered in ClinicalTrials.gov with ScandiBio Therapeutics AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
- Lead sponsor
- ScandiBio Therapeutics AB
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 12, 2025
- Completion date
- September 30, 2026
- Enrollment
- 845 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.